A monthly column devoted to IP curiosities and controversies, named in honour of John of Utynam - who received the world's first recorded patent in 1449
The drug that dare not speak its name
Utynam was pleased to receive a piece of news from a Chinese law firm about Pfizer's recent victory in a Beijing court over a patent related to its anti-impotence drug Viagra.
In an email accompanying a press release prepared by Peksung, which advised Pfizer in its long-running dispute with a group of Chinese companies over the patent, the sender informed Utynam that "a decision was made today by Beijing Higher Court regarding the Chinese patent on Pfizer's popular drug".
Utynam thought little more of Peksung's enigmatic refusal to name its client's blockbuster drug until he sent a reply thanking the firm for its timely update on developments in the Viagra case. The email bounced back having been rejected by the firm's electronic gatekeepers for containing a banned keyword.
Utynam is intrigued to know how Pfizer's in-house...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of one week’s FREE access
and become a Managing IP member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain 7 days FREE access when you register now.